Chris started his career as a researcher in BBC Television’s documentaries department and then became a financial journalist. He was previously Investment Banking Correspondent and Senior Corporate Reporter at the Financial Times, Financial Editor of The Independent and a companies writer at the Investors Chronicle. Chris has also worked at communications consultancy Financial Dynamics (now FTI), as an Associate Partner.
- Tel: +44 (0)20 7542 2410
- E-mail: firstname.lastname@example.org
Britain’s top antitrust watchdog has warned lenders to expect a full-blown competition investigation. Forced divestments would be a surprising outcome. But given the persistence of concern in spite of past probes, investors should brace for radical, profit-sapping remedies.
The UK tobacco group wants to acquire assets sold following a possible merger of U.S. peers Reynolds and Lorillard. Imperial may win a path to scale in America. But the positive market reaction is too sanguine about balance-sheet strain and the acquisition of low-growth assets.
Independent advisers are popular on European new issues. Now the bookrunners they police are moaning that their presence leads to overpriced floats. While the charge looks spurious, the row points to the need for transparency in the role of sell-side analysts during IPOs.
- AbbVie hints it can afford to pay more for Shire
- UK hacking verdicts could embolden Murdoch
- Value puzzle impedes hedge fund founder's divorce
- Failed bid would leave Astra under pressure
- Astra-Pfizer needs a fresh start later in the year
- Loophole offers Pfizer risky way back into AZ deal
- AstraZeneca gets a summer reprieve